Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

U.S. drugmaker J&J's India sales dip 3 percent in 2017/18: filing

Published 01/03/2019, 03:25 AM
Updated 01/03/2019, 03:25 AM
© Reuters. A bottle of Johnson's Baby Powder is seen in a photo illustration taken in New York

© Reuters. A bottle of Johnson's Baby Powder is seen in a photo illustration taken in New York

NEW DELHI (Reuters) - Johnson & Johnson's (N:JNJ) sales in India dipped 3 percent in the year to March 2018, a regulatory filing showed on Thursday, as the U.S. drugmaker grappled with the country's stringent medical device pricing policies.

The company, currently mired in a controversy surrounding the safety of its baby talcum powder, reported overall sales of 58.28 billion rupees ($829 million) in India for the year, its filing with the country's Ministry of Corporate Affairs shows.

But its after-tax profit for the period rose 18 percent to $98 million on other income, including foreign exchange gains.

J&J's medical device sales in India have been hit following the federal government's move in 2017 to cap prices of devices such as orthopedic knee implants to help poor patients.

The restrictions were part of a broader push by India to end what it called "illegal profiteering" by companies.

The company has recently been in the news after a Reuters investigation found J&J knew for decades that cancer-causing asbestos lurked in its baby powder.

The report prompted drug inspectors across India to collect talc samples from J&J facilities for testing.

J&J has said the Reuters article was "one-sided, false and inflammatory", adding that its Baby Powder was "safe and asbestos free".

J&J's Baby Powder is one of the most recognized foreign brands in India. The company leads sales in the Indian baby and child toiletries market, which Euromonitor International estimates was worth $178 million last year.

J&J's consumer segment in India, which includes baby care products such as soap and talc, recorded sales of 31 billion rupees in the year to March 2018, marginally lower than the previous year, the company's India filing showed.

Sales in its medical segment, which includes its orthopedic products, fell 7 percent to 19.6 billion rupees.

© Reuters. A bottle of Johnson's Baby Powder is seen in a photo illustration taken in New York

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.